Vistagen acquires Pherin Pharmaceuticals for 12.4M shares and 'nominal' cash

Two psychiatric-based drug development companies, Vistagen and Pherin Pharmaceuticals, are merging in a deal worth 12.4 million shares and a “nominal amount” of cash, Vistagen announced Wednesday.